Is Retatrutide FDA Approved?

Retatrutide is not approved by the FDA. It remains an investigational compound, currently in phase 3 clinical trials, and no brand version exists on pharmacy shelves.

What "phase 3" actually means here

Drug development in the United States moves through a fixed sequence before the FDA will even review an application: phase 1 (safety, small groups), phase 2 (dose-finding, efficacy signals), and phase 3 (larger, longer trials meant to confirm effect and surface rarer side effects). Only after phase 3 data is submitted can the FDA approve a drug for sale.

Retatrutide's phase 2 results were published in the New England Journal of Medicine. Jastreboff et al., NEJM 2023 reported the trial in adults with obesity, and a separate phase 2 trial in type 2 diabetes was reported by Rosenstock et al., Lancet 2023. The compound has since moved into phase 3: Jastreboff et al., NEJM 2026 reports a phase 3 trial of retatrutide for obesity. Phase 3 is the stage directly before an FDA filing — it is not the same as approval, and there is no set date by which a phase 3 program finishes.

Anyone can check the current status of the ongoing trials directly at ClinicalTrials.gov, which lists each registered study, its phase, and its recruitment status. That registry is the most current source — more current than any blog post, including this one.

Why people confuse retatrutide with an approved drug

Retatrutide belongs to the same drug class as several medications the FDA has already approved. It's a triple agonist, acting on GLP-1, GIP, and glucagon receptors — one receptor more than the dual-agonist tirzepatide. Because tirzepatide is sold as Mounjaro and Zepbound, and semaglutide (a single GLP-1 agonist) is sold as Ozempic and Wegovy, people searching for retatrutide often assume it has reached the same point. It hasn't.

The mechanism comparison is worth being precise about, since the three compounds are frequently discussed together:

Being in the same drug class as an approved medication tells you something about mechanism. It tells you nothing about regulatory status — each molecule is reviewed and approved (or not) on its own trial data.

What the trials have actually measured

The phase 2 obesity trial compared different weekly doses of retatrutide against placebo over roughly a year, tracking body weight change as the primary measure. The type 2 diabetes trial tracked glycemic markers across a similar dosing range. The phase 3 obesity trial published in 2026 extends that work with a larger population and longer follow-up — the kind of data the FDA requires before it will consider an application. None of these publications are a substitute for an FDA review, and none of them constitute an approval or a safety clearance for use outside a monitored trial.

Where PeptoClinic fits into this

PeptoClinic lists retatrutide in its catalog, analyzed by Janoshik Analytical with a published purity of 99.893% for the retatrutide lot tested. That certificate speaks to the purity of the material supplied — it has no bearing on the FDA's review of the compound as a drug. PeptoClinic's retatrutide is not Mounjaro, not Zepbound, and not any approved product; it is not approved by the FDA, full stop, regardless of how the material is sourced or verified. A physician reviews each consultation before anything ships, and pricing for everything in the catalog is published at /en/pricing/.

Anyone comparing suppliers should also look at how material travels and what quality documentation is provided alongside it — a certificate of analysis is the one claim in this space that resolves to a document rather than a marketing line.